RxDoctor Payments Data

Meilyn Reyes Perez, MD

Internal Medicine · San Juan, PRNPI 1497867063

Payments from drug & device makers

$1,353in general payments, 2019–2025

Across 41 payments — averaging $33.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer Puerto Rico Inc.$326
  • AstraZeneca$199
  • Boehringer Ingelheim$127
  • Mallinckrodt Enterprises LLC$125
  • Genentech USA, Inc.$117
  • E.r. Squibb & Sons, L.L.C.$100
  • plus $359 from 8 others

What the payments were for

  • Food & beverage$1,353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,353 in reported general payments places this provider in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,808
Medicare patients
49
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide203$205,145
JanuviaSitagliptin Phosphate204$151,527
FarxigaDapagliflozin Propanediol166$114,078
JanumetSitagliptin Phos/Metformin Hcl100$92,606
Xigduo XrDapaglifloz Propaned/Metformin95$89,473
OzempicSemaglutide80$79,241
EliquisApixaban91$77,069
SynjardyEmpagliflozin/Metformin Hcl92$71,915
JardianceEmpagliflozin88$61,143
XareltoRivaroxaban71$59,253
ProliaDenosumab27$47,527
SynthroidLevothyroxine Sodium470$46,682
GlyxambiEmpagliflozin/Linagliptin51$45,421
MounjaroTirzepatide28$29,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$42$244,133304 claims
Boehringer IngelheimSynjardy, Jardiance, Glyxambi, Trijardy Xr, Synjardy Xr$127$212,455283 claims
AstraZenecaFarxiga, Breztri Aerosphere$199$134,097197 claims
Johnson & JohnsonXarelto$46$59,25371 claims
AbbVieSynthroid$25$46,682470 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$34$31,370136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →